Study Summary
This trial tests a new medicine to treat Major Depressive Disorder (MDD). It is a safe, controlled study with real medicine and placebo.
- Major Depressive Disorder
- Depression
- Major Depressive Episode
- Severe Depression
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 2 Secondary · Reporting Duration: Day 1 and Week 6
Trial Safety
Phase-Based Safety
Trial Design
2 Treatment Groups
TNX-601 ER, 39.4 mg
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
300 Total Participants · 2 Treatment Groups
Primary Treatment: TNX-601 ER, 39.4 mg · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 65 · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are elderly individuals accepted into the research trial?
"The requirements for entering this clinical trial stipulate that the minimum age must be 18 and no older than 65." - Anonymous Online Contributor
How many individuals are participating in the scientific experiment?
"Affirmative. The clinicaltrials.gov website details that this trial, which was posted on March 2nd 2023 and updated 13 days later, is currently searching for 300 volunteers to be enrolled at one location." - Anonymous Online Contributor
Are there any open slots for volunteers in this research endeavor?
"Per the clinicaltrials.gov database, this medical study is actively seeking volunteers for participation; having first been posted on March 2nd 2023 and most recently updated on March 13th of the same year." - Anonymous Online Contributor
Is it possible to join this clinical research program?
"To be eligible for enrollment in this clinical trial, participants must have a diagnosis of depression and fall within the age range 18 to 65. The study is hoping to recruit approximately 300 qualified individuals." - Anonymous Online Contributor
Has the FDA sanctioned TNX-601 ER, 39.4 mg for public use?
"Our assessment of TNX-601 ER, 39.4 mg's safety is a 2 because there has been some evidence collected in regards to its safety but none which can support its efficacy yet." - Anonymous Online Contributor